ライフサイエンスコーパス: beta2 adrenergic receptor

1 aits via binding to various receptors (e.g., beta2-adrenergic receptor).

2 us positions in purified preparations of the beta2 adrenergic receptor.

3 and the modulation of these channels by the beta2 adrenergic receptor.

4 bserved in Galphas upon binding of Gs to the beta2 adrenergic receptor.

5 ion of both the transferrin receptor and the beta2 adrenergic receptor.

6 to recruit the ubiquitin ligase Nedd4 to the beta2-adrenergic receptor.

7 prototypical recycling membrane protein, the beta2-adrenergic receptor.

8 lin, and PDE4D (phosphodiesterase 4D) to the beta2-adrenergic receptor.

9 tions of the potential energy surface of the beta2-adrenergic receptor.

10 rnalization of a set of mutants of the human beta2-adrenergic receptor.

11 or the activation of the MAPK pathway by the beta2-adrenergic receptor.

12 ne (Gly/Gly), at aminoacid residue 16 of the beta2-adrenergic receptor.

13 e Arg16Gly and Gln27Glu polymorphisms of the beta2-adrenergic receptor.

14 5 and TM6), similar to that observed for the beta2-adrenergic receptor.

15 nophosphate phosphodiesterases to Gs-coupled beta2-adrenergic receptors.

16 bligate for resensitization and recycling of beta2-adrenergic receptors.

17 d receptors, including alpha2A, alpha2B, and beta2-adrenergic receptors.

18 of terbutaline is mediated by activation of beta2-adrenergic receptors.

19 Pharmacologic inhibition of beta2-adrenergic receptor 2 and protein kinase A, as wel

20 cells up-regulated Adrb2 (which encodes the beta2-adrenergic receptor), a process dependent on IL-12

21 Subsequently, we identified the beta2 adrenergic receptor (ADRB2) as a downstream target

22 Polymorphisms in the beta2 adrenergic receptor (ADRB2), in particular G16R, Q

23 re prevented by treatment with the selective beta2-adrenergic receptor (ADRB2) antagonist ICI118,551

24 previous study, the Gly16Arg genotype of the beta2-adrenergic receptor (ADRB2) gene did not influence

25 with reduced expression of the gene for the beta2-adrenergic receptor (ADRB2) in CD4(+) lymphocytes

26 mozygous for arginine at aminoacid 16 of the beta2-adrenergic receptor (ADRB2) might not benefit from

27 The effect of beta2-adrenergic receptor (ADRB2) polymorphisms on the t

28 receptor target of beta-agonist therapy, the beta2-adrenergic receptor (ADRB2).

29 Sympathetic signalling via beta2-adrenergic receptors (Adrb2) present on osteoblast

30 ell-specific analysis of the function of the beta2 adrenergic receptor (Adrbeta2) and various genes i

31 enotype at the 16th aminoacid residue of the beta2-adrenergic receptor affects the long-term response

32 s alone or in combination with a long-acting beta2 -adrenergic receptor agonist (LABA) on GCM in the

33 dependent stimulation of beating rate by the beta2 adrenergic receptor agonist procaterol was signifi

34 yses revealed that formoterol, a long-acting beta2 adrenergic receptor agonist, caused significant im

35 in the rat cerebral cortex is induced by the beta2-adrenergic receptor agonist clenbuterol (CLE).

36 Here, we show that treatment with the beta2-adrenergic receptor agonist clenbuterol increases

37 ency can also benefit from the addition of a beta2-adrenergic receptor agonist to their medication.

38 Salmeterol is a long-acting beta2-adrenergic receptor agonist used to treat chronic

39 or treating airway obstructive diseases, and beta2 adrenergic receptor agonists have been the most co

40 nition in Ts65Dn mice, formoterol or similar beta2 adrenergic receptor agonists with ability to cross

41 y of commonly used asthma therapies, such as beta2-adrenergic receptor agonists (beta-agonists).

42 ing mechanism of Rett syndrome and introduce beta2-adrenergic receptor agonists as potential therapeu

43 empty G-protein binding site of an activated beta2 adrenergic receptor and form salt-bridge interacti

44 mized models incorporating the structures of beta2-adrenergic receptor and 5-HT2B receptor.

45 gamma receptor, a polymorphism marker in the beta2-adrenergic receptor and a low-inducible allele of

46 ased on the recent crystal structures of the beta2-adrenergic receptor and A2a-adenosine receptor.

47 gion of a constitutively active mutant human beta2-adrenergic receptor and attaching Renilla reniform

48 n of the LCP-Tm assay to an engineered human beta2-adrenergic receptor and bacteriorhodopsin revealed

49 Thus, signaling via the erythrocyte beta2-adrenergic receptor and Galphas may regulate malar

50 ave found that signaling via the erythrocyte beta2-adrenergic receptor and heterotrimeric guanine nuc

51 After protracted stimulation, the beta2-adrenergic receptor and many other G-protein-coupl

52 ptor b2, whereas two Rhodopsin-family GPCRs, beta2-adrenergic receptor and mCannR2, exhibit colocaliz

53 Using the beta2-adrenergic receptor and rhodopsin as receptor subs

54 structures: the adenosine A2A receptor, the beta2-adrenergic receptor and rhodopsin.

55 -binding and transmembrane segments from the beta2-adrenergic receptor and the cytoplasmic domains fr

56 y feature of the EE effect was activation of beta2-adrenergic receptors and downstream cAMP/PKA signa

57 protein (GFP)-arr3 in live cells expressing beta2-adrenergic receptors and fluorescent CL.

58 iated activation of RhoA in AEC occurred via beta2-adrenergic receptors and involved Gs-PKA as demons

59 tudies demonstrating disparate regulation of beta2-adrenergic receptors and microRNA between pediatri

60 nd epinephrine, proceeding through the beta1/beta2-adrenergic receptors and protein kinase A, resulti

61 he immunocomplex between a membrane protein, beta2 adrenergic receptor, and anti-FLAG antibody has be

62 ing the crystal structures of rhodopsin, the beta2-adrenergic receptor, and the ligand-free opsin, wh

63 ippocampal LTP, decreased neuronal levels of beta2-adrenergic receptors, and activated microglia in w

64 ), cecal peritonitis with dopexamine and the beta2-adrenergic receptor antagonist ICI 118,551 (n = 4)

65 mimicked by administration of the selective beta2-adrenergic receptor antagonist ICI-118,551.

66 Cotreatment with a beta2-adrenergic receptor antagonist, butoxamine, sugges

67 were subjected to the nonselective (beta1 + beta2) adrenergic receptor antagonists propranolol or na

68 We report the 3D structure of human beta2 adrenergic receptor (AR) predicted by using the Me

69 However, ISO response was reversed by beta2-adrenergic receptor (AR) inhibition.

70 er kidney cells, the human beta1-but not the beta2-adrenergic receptor (AR) is totally resistant to a

71 yocardial contractile response to beta1- and beta2-adrenergic receptor (AR) stimulation is severely i

72 es exist after stimulation of the beta1- and beta2-adrenergic receptor (AR) subtypes.

73 the angiotensin II type 1A receptor (AT1R), beta2-adrenergic receptor (AR), and alpha2B-AR in HEK293

74 s (BF) and heavy/non-buoyant fractions (HF); beta2-adrenergic receptors (AR) in BF; and AC5/6, beta1-

75 beta1- and beta2-adrenergic receptors (AR) regulate cardiac myocyte

76 owever, in contrast to the activation of the beta2-adrenergic receptor, arrestin was not necessary fo

77 Using the beta2-adrenergic receptor as a model, we present a proof

78 estin-3 and its 3A mutant that readily binds beta2-adrenergic receptors as well as two mutants impair

79 Real-time cAMP analysis in beta1- and beta2-adrenergic receptor-associated membrane microdomai

80 inine at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) benefit less fro

81 tudies showed that epinephrine activates the beta2-adrenergic receptor (B2AR), impairing keratinocyte

82 The luteinizing hormone receptor (LHR) and beta2-adrenergic receptor (B2AR), two GPCRs sorted to th

83 cardiac death (SCD), mediated in part by the beta2-adrenergic receptor (B2AR).

84 One of the defining properties of beta2-adrenergic receptor (beta(2)AR) signaling is the t

85 n the tumor microenvironment is regulated by beta2-adrenergic receptor (beta-AR) signaling in host im

86 ompartmentalize cAMP signaling transduced by beta2-adrenergic receptors (beta(2)ARs); such compartmen

87 Cardiomyocyte beta2-adrenergic receptors (beta-ARs) provide a source o

88 multiple conformational states of a phospho-beta2 adrenergic receptor/beta-arrestin-1(beta-arr1) mem

89 study, we report that mice with no beta1- or beta2-adrenergic receptors (beta1AR-/-/beta2AR-/-) have

90 Recent research has revealed that beta2 -adrenergic receptor (beta2 -AR) agonists lose bro

91 nificant elevation of phosphorylation of the beta2 -adrenergic receptor (beta2 AR) at both the protei

92 Mouse and human CPCs express only beta2 adrenergic receptor (beta2-AR) in conjunction with

93 Previously, we demonstrated that beta2-adrenergic receptor (beta2-AR) activation in kerat

94 cAMP stimulated by two Gs-coupled receptors, beta2-adrenergic receptor (beta2-AR) and D1 dopamine rec

95 It is well established that the beta2-adrenergic receptor (beta2-AR) exhibits a robust l

96 This study examines the role of the beta2-adrenergic receptor (beta2-AR) in cardioprotection

97 publication of the crystal structure of the beta2-adrenergic receptor (beta2-AR) proved that G prote

98 ll phenotypic pharmacology of ligands at the beta2-adrenergic receptor (beta2-AR) stably expressed in

99 They solely express the beta2-adrenergic receptor (beta2-AR) subtype of beta-ARs

100 endent activation and internalization of the beta2-adrenergic receptor (beta2-AR), a prototypic G-pro

101 eport here that following stimulation of the beta2-adrenergic receptor (beta2-AR), a prototypical 7TM

102 phosphorylated form of the G protein-coupled beta2-adrenergic receptor (beta2-AR), have recently emer

103 pendent phosphate cotransporter (Npt2a), and beta2-adrenergic receptor (beta2-AR), through their resp

104 We demonstrate here a role for the beta2-adrenergic receptor (beta2-AR), which binds the st

105 ribute to selective interactions between the beta2-adrenergic receptor (beta2-AR)-Galphas and V1A rec

106 itide 3-kinase (PI3K) has been implicated in beta2-adrenergic receptor (beta2-AR)/G(i)-mediated compa

107 Keratinocytes express a high level of beta2-adrenergic receptors (beta2-ARs) that appear to pl

108 o the plasma membrane upon coexpression with beta2-adrenergic receptors (beta2-ARs) through an intera

109 g bone deposition and resorption through the beta2-adrenergic receptors (beta2-ARs).

110 ssing the stimulatory G protein fused to the beta2 adrenergic receptor (beta2AR) and AC were incubate

111 ism of their activation process, as only the beta2 adrenergic receptor (beta2AR) and rhodopsin have b

112 The role of the beta2 adrenergic receptor (beta2AR) in the regulation of

113 carboxyl-terminal cytoplasmic domain of the beta2 adrenergic receptor (beta2AR) mediates both PDZ bi

114 Engagement of the beta2 adrenergic receptor (beta2AR) on a B cell is known

115 helix 6 (Cys-265), (19)F NMR spectra of the beta2 adrenergic receptor (beta2AR) reconstituted in mal

116 (Cmpd-15) is an allosteric modulator of the beta2 adrenergic receptor (beta2AR) that was recently is

117 fer imaging, we examine TM6 movements in the beta2 adrenergic receptor (beta2AR) upon exposure to ort

118 we reconsider oligomerization of the class A beta2 adrenergic receptor (beta2AR), and reevaluate BRET

119 adenosine 2B receptor (A2BR), but not of the beta2 adrenergic receptor (beta2AR), leading to an enhan

120 ing the membrane-proximal amino acids of the beta2 adrenergic receptor (beta2AR), the sphingosine 1-p

121 uestion by comparing human Wntless (Wls) and beta2 adrenergic receptor (beta2AR), which require retro

122 We observed that in beta2 adrenergic receptor (beta2AR)-expressing HEK-293 c

123 ral data on a number of GPCRs, including the beta2 adrenergic receptor (beta2AR)-G-protein complex, h

124 vated protein (MAP) kinase activation by the beta2 adrenergic receptor (beta2AR).

125 re we show in atomistic detail how the human beta2-adrenergic receptor (beta2AR) - a prototypical G p

126 In this article, we demonstrate that beta2-adrenergic receptor (beta2AR) activation in LPS-st

127 Salmeterol is a long-acting beta2-adrenergic receptor (beta2AR) agonist that is wide

128 cle hypertrophy stimulated by clenbuterol, a beta2-adrenergic receptor (beta2AR) agonist, was signifi

129 beta2-adrenergic receptor (beta2AR) agonists are a mains

130 beta2-Adrenergic receptor (beta2AR) agonists are critica

131 l and small clinical studies have shown that beta2-adrenergic receptor (beta2AR) agonists enhance AFC

132 PCL interacts with beta2-adrenergic receptor (beta2AR) and co-localizes wit

133 he model G-protein-coupled receptors (GPCRs) beta2-adrenergic receptor (beta2AR) and Mu-opioid recept

134 y we predicted the 3D structure of the human beta2-adrenergic receptor (beta2AR) and of the binding s

135 In addition to phosphorylating the beta2-adrenergic receptor (beta2AR) and other receptors,

136 observed for agonist-bound structures of the beta2-adrenergic receptor (beta2AR) and the M2 muscarini

137 The crystal structure of the beta2-adrenergic receptor (beta2AR) bound to the G prote

138 Adenoviral-mediated rescue of beta2-adrenergic receptor (beta2AR) function into the al

139 nucleotide polymorphisms (SNPs) in the human beta2-adrenergic receptor (beta2AR) gene.

140 ous for arginine (ArgArg) at codon 16 of the beta2-adrenergic receptor (beta2AR) have been shown to h

141 participating in the phosphorylation of the beta2-adrenergic receptor (beta2AR) have in part been li

142 r (CB1-Gi), guided by the x-ray structure of beta2-adrenergic receptor (beta2AR) in complex with Gs (

143 noprecipitated with overexpressed TPbeta and beta2-adrenergic receptor (beta2AR) in HEK 293 cells, bu

144 rine network exists in skin, but the role of beta2-adrenergic receptor (beta2AR) in wound healing is

145 The beta2-adrenergic receptor (beta2AR) is a prototypical G

146 The beta2-adrenergic receptor (beta2AR) is a well-studied pr

147 Agonist-stimulated desensitization of the beta2-adrenergic receptor (beta2AR) is caused by both a

148 Although the beta2-adrenergic receptor (beta2AR) is the most extensiv

149 release of catecholamines, which engage the beta2-adrenergic receptor (beta2AR) on murine alveolar m

150 strated that photoactivation of gelsolin and beta2-adrenergic receptor (beta2AR) optobodies suppresse

151 rine models of asthma, agonist-activation of beta2-adrenergic receptor (beta2AR) or Protease-activate

152 beta2-Adrenergic receptor (beta2AR) plays a critical rol

153 The beta2-adrenergic receptor (beta2AR) plays important phys

154 y determined crystal structures of the human beta2-adrenergic receptor (beta2AR) provide a long-await

155 Efficient recycling of the beta2-adrenergic receptor (beta2AR) requires a C-termina

156 Dietary Na+ intake influences beta2-adrenergic receptor (beta2AR) responsiveness.

157 lphas-CFP, YFP-N-beta1/YFP-C-gamma7, and the beta2-adrenergic receptor (beta2AR) resulted in internal

158 -coupled receptor kinases (GRKs) desensitize beta2-adrenergic receptor (beta2AR) signaling, and these

159 by a B cell is increased following CD86 and beta2-adrenergic receptor (beta2AR) stimulation, through

160 Here, we identify beta2-adrenergic receptor (beta2AR) that mediates Abeta-

161 al dynamics of the cytoplasmic domain of the beta2-adrenergic receptor (beta2AR) using (19)F-fluorine

162 (GRK) site phosphoserines 355 and 356 of the beta2-adrenergic receptor (beta2AR) were characterized i

163 ort the requirement of an association of the beta2-adrenergic receptor (beta2AR) with the pore formin

164 we demonstrate that a prototypical GPCR, the beta2-adrenergic receptor (beta2AR), can be incorporated

165 specific Cy3 fluorescence probe in the human beta2-adrenergic receptor (beta2AR), we observed that in

166 this study, we describe for the first time a beta2-adrenergic receptor (beta2AR)-activating monoclona

167 The suppression was prevented when a beta2-adrenergic receptor (beta2AR)-selective agonist wa

168 docking to analyze GRK5 interaction with the beta2-adrenergic receptor (beta2AR).

169 e ensemble of conformations sampled by human beta2-adrenergic receptor (beta2AR).

170 ARRDC3 in regulating the trafficking of the beta2-adrenergic receptor (beta2AR).

171 and stabilize an active conformation of the beta2-adrenergic receptor (beta2AR).

172 in three different conformational states of beta2-adrenergic receptor (beta2AR): 1), the inverse-ago

173 hma, the response to beta-agonists acting at beta2-adrenergic receptors (beta2AR) displays extensive

174 We find, however, that co-expression of beta2-adrenergic receptors (beta2AR) in HEK-293T routes

175 We report here that a population of human beta2-adrenergic receptors (beta2AR), a canonical G prot

176 afficking and recycling of agonist-activated beta2 adrenergic receptors (beta2ARs).

177 We previously demonstrated the importance of beta2-adrenergic receptors (beta2ARs) in the regulation

178 Agonist stimulation of the beta2-adrenergic receptors (beta2ARs) leads to their ubi

179 The beta2-adrenergic receptors (beta2ARs) play a role in ren

180 ficant population of Galphai and its coupled beta2-adrenergic receptor (betaAR), are localized to cav

181 Beta1- and beta2-adrenergic receptors (betaARs) are highly homologo

182 through adrenergic receptors (ARs), of which beta2-adrenergic receptors (betaARs) are of particular i

183 The beta1- and beta2-adrenergic receptors (betaARs) on the surface of c

184 Conversely, selective beta2 adrenergic receptor blockade did not affect MCFP r

185 ectomy, ganglionic-blocker administration or beta2-adrenergic receptor blockade.

186 beta2-Adrenergic receptor blocker treatment reduced arrh

187 Here we report on the dynamics of the beta2 adrenergic receptor bound to the beta-arrestin and

188 The structures of beta2-adrenergic receptor bound with a variety of ligand

189 Catecholamines signal through the beta2-adrenergic receptor by promoting production of the

190 -regulating genes (those encoding beta1- and beta2-adrenergic receptors, calcium ATPase in the sarcop

191 Strikingly, the beta2 adrenergic receptor can substitute for an OR in gl

192 cent high resolution x-ray structures of the beta2-adrenergic receptor confirmed a close salt-bridge

193 We found that in Src-deficient cells the beta2-adrenergic receptor could activate the MAPK pathwa

194 receptor (DOR) molecular model based on the beta2-adrenergic receptor crystal structure are explored

195 this study we have defined a sequence in the beta2-adrenergic receptor cytoplasmic tail that confers

196 In further mechanistic studies using beta2-adrenergic receptor-deficient (beta2-AR(-/-)) mice

197 nase A-dependent manner, an effect lost when beta2-adrenergic receptor-deficient B cells were used.

198 is of the delta-opioid receptor, but not the beta2-adrenergic receptor, defining a role for CLCs in t

199 Further, we demonstrate that beta2-adrenergic receptor-dependent activation of proinf

200 Importantly, phosphorylation of the inactive beta2-adrenergic receptor enhanced its interactions with

201 Time-lapse imaging of the beta2 adrenergic receptor expressed in cultured rat hipp

202 We used this microfluidic device to quantify beta2 adrenergic receptors expressed in insect cells (SF

203 xpress the beta1-adrenergic receptor with no beta2-adrenergic receptor expression observed.

204 We demonstrate the utility of beta2-adrenergic receptor-Frizzled chimeras to provide t

205 orters; and 2), rhodopsin and the beta1- and beta2-adrenergic receptors from the G-protein coupled re

206 , variation in haplotype frequencies for the beta2 adrenergic receptor gene was found to be associate

207 The beta2-adrenergic receptor gene (ADRB2) contains a common

208 Variants of beta2-adrenergic receptor gene (ADRB2) have been associa

209 s important in understanding the function of beta2-adrenergic receptor gene (ADRbeta2) on disease sus

210 6 to 6.09; P=0.001; FDR, P=0.036) and a Q27E beta2-adrenergic receptor gene polymorphism (OR, 1.40; 9

211 There was no association of beta2-adrenergic receptor genotype with ischemic stroke

212 Pase exocytosis in AEC via the activation of beta2-adrenergic receptor, Gs, PKA, Gi, RhoA, and ROCK.

213 ealed an architecture similar to that of the beta2-adrenergic receptor-GS complex, including a flexib

214 FTR overexpression in mice with no beta1- or beta2-adrenergic receptors had no effect on AFC.

215 %, respectively, P = 0.003), irrespective of beta2-adrenergic receptor haplotype.

216 3%, respectively, P = 0.01), irrespective of beta2-adrenergic receptor haplotype.

217 tic polymorphisms at codons 16 and 27 of the beta2-adrenergic receptor have been associated with alte

218 active and active experimental structures of beta2 adrenergic receptor (hbeta2AR) and M2 muscarinic a

219 We conclude that beta1- and beta2-adrenergic receptor homodimers with TM1/H8 at the

220 ere consistent with the crystal structure of beta2 adrenergic receptor in complex with Gs Conformatio

221 s simulations to explore dimerization of the beta2-adrenergic receptor in lipid bilayers containing c

222 Colocalization of CB1 and beta2-adrenergic receptors in the oviduct muscularis imp

223 th processes by recruiting PDEs to activated beta2-adrenergic receptors in the plasma membrane of mam

224 sing a model G protein-coupled receptor, the beta2-adrenergic receptor, including experiments that ch

225 transfer studies using mice lacking beta2AR (beta2 adrenergic receptors) indicate that beta2AR in the

226 Also, the beta2-adrenergic receptor-induced increase in the level

227 and beta-arrestin 2 play essential roles in beta2-adrenergic receptor internalization, they are not

228 n with mu-adaptin and the ability to enhance beta2-adrenergic receptor internalization.

229 Our data suggest that targeting beta2 adrenergic receptors is an effective strategy for

230 The beta2-adrenergic receptor is an important member of the

231 the prototypical G protein-coupled receptor beta2-adrenergic receptor is partially preassociated in

232 Although the location of carazolol in the beta2-adrenergic receptor is very similar to that of ret

233 of endothelial Adrb2, the gene encoding the beta2-adrenergic receptor, leads to inhibition of angiog

234 ly relevant responses was corroborated using beta2-adrenergic receptor ligands.

235 found that downregulation of Rnd3 attenuated beta2-adrenergic receptor lysosomal targeting and ubiqui

236 ous for arginine at the 16th position of the beta2-adrenergic receptor may not benefit from short-act

237 a critical role for C/EBPdelta in regulating beta2-adrenergic receptor-mediated NGF expression in viv

238 of hippocampal synaptic plasticity including beta2-adrenergic receptor-mediated plasticity, and selec

239 rder, have been associated with IgGs against beta2-adrenergic receptor, muscarinic-2 receptors, AChR-

240 t muscularis and norepinephrine signaling to beta2 adrenergic receptors on MMs.

241 of CD86 (formerly known as B7-2) and/or the beta2-adrenergic receptor on a CD40 ligand/interleukin-4

242 Here we show that a chimeric rhodopsin/beta2 adrenergic receptor (opto-beta2AR) is similar in d

243 meric receptor composed of rhodopsin and the beta2-adrenergic receptor (Opto-beta2AR) with in vivo op

244 MRAP did not alter expression of beta2-adrenergic receptors or co-precipitate with them.

245 evealed that recruitment of arrestin3 to the beta2-adrenergic receptor orchestrates the sequestration

246 tural analysis of two other GPCRs, beta1 and beta2 adrenergic receptors, our results could reveal a g

247 act ventricular myocytes via both beta1- and beta2-adrenergic receptor pathways, but the beta2-depend

248 ch is associated with significant changes in beta2 -adrenergic receptor phosphorylation at protein ki

249 Furthermore, both hippocampal beta2-adrenergic receptor phosphorylation by PKA, and le

250 sis in prostate cancer cells via epinephrine/beta2 adrenergic receptor/PKA/BAD pathway.

251 Blockade of alpha1/alpha2- and beta1/beta2-adrenergic receptors prevented the stress-induced

252 anglionectomy or pharmacological blockade of beta2-adrenergic receptors prevents NPPE release into th

253 ne rhodopsin and the recently released human beta2 adrenergic receptor protein structure.

254 , which in turn resulted in the elevation of beta2-adrenergic receptor protein levels leading to the

255 y, betaarr1 in complex with M2 muscarinic or beta2-adrenergic receptors reconstituted in lipid nanodi

256 ent high-resolution crystal structure of the beta2-adrenergic receptor revealed the presence of possi

257 the signaling profiles of 28 variants of the beta2-adrenergic receptor reveals three clearly distinct

258 tes is able to normalize the distribution of beta2 adrenergic receptor signal by preventing PKA signa

259 n the myofilaments is because of an enhanced beta2 adrenergic receptor signal selectively directed to

260 We further demonstrate that the endosomal beta2-adrenergic receptor signal confers uniformity on t

261 ntroduction of caveolin-3 is able to confine beta2 adrenergic receptor signaling and restore myocyte

262 rophic rabbit myocytes, selectively enhanced beta2 adrenergic receptor signaling toward the myofilame

263 pool of PKA that regulates learning-induced beta2-adrenergic receptor signaling and ERK activation i

264 rosine kinases to examine the role of Src in beta2-adrenergic receptor signaling to the MAPK pathway

265 receptor internalization is not required for beta2-adrenergic receptor signaling to the MAPK pathway

266 h high-fat diet (HFD) feeding on the cardiac beta2 -adrenergic receptor signalling and the impacts on

267 Beta2-adrenergic receptor stimulation increased CREB pho

268 is effect, we determined whether CD86 and/or beta2-adrenergic receptor stimulation regulated transcri

269 C- and NF-kappaB1-dependent manner, and that beta2-adrenergic receptor stimulation up-regulates the e

270 haracterized a homogeneous population of the beta2 adrenergic receptor subtype expressed on these cel

271 We report the crystal structure of a human beta2-adrenergic receptor-T4 lysozyme fusion protein bou

272 -AR chimera containing the type I PDZ of the beta2-adrenergic receptor that does not bind to SAP97 fa

273 GE(2) by > 50%; (ii) had no effect on EP4 or beta2 adrenergic receptors, the cAMP assay itself, or th

274 eral G protein-coupled receptors such as the beta2-adrenergic receptor, the kappa-opioid receptor, an

275 Cav1.2 forms a complex with the beta2-adrenergic receptor, the trimeric GS protein, aden

276 In the case of the beta2 adrenergic receptor, these ligands are generally s

277 ine Ca2+ influx, and can be modulated by the beta2 adrenergic receptor through PKA in a highly compar

278 of ligands and investigated their impacts on beta2-adrenergic receptor through a total of 12 x 100 ns

279 Control studies established that the beta2-adrenergic receptor TM VI peptide that disrupts ol

280 thereby explaining failure of the wild type beta2-adrenergic receptor to recycle efficiently by defa

281 ol-sensitive AFC in mice with beta1- but not beta2-adrenergic receptors to beta1AR-/-/beta2AR-/- mice

282 A beta2-adrenergic receptor truncated distal to residue 38

283 by a mechanism that attenuates Rnd3-mediated beta2-adrenergic receptor ubiquitination, which leads to

284 ity to map the oligomerization energy of the beta2-adrenergic receptor using approximately 10(9)-fold

285 The Glu27 allele of the beta2-adrenergic receptor was associated with a lower ri

286 n beta-arrestin 2 the internalization of the beta2-adrenergic receptor was impaired, whereas the acti

287 as the activation of the MAPK pathway by the beta2-adrenergic receptor was normal.

288 In HEK 293 cells, the G(s)-coupled beta2-adrenergic receptor was postulated to initiate a s

289 However, the internalization of beta2-adrenergic receptors was blocked in Src-deficient

290 g data for a set of small molecules with the beta2 adrenergic receptor, we demonstrate that deconvolu

291 Starting from the crystal structure of the beta2-adrenergic receptor, we have used coarse grain com

292 for homomers of the cognate human beta1- and beta2-adrenergic receptors, we have carried out approxim

293 rged amino acids in the proximal tail of the beta2-adrenergic receptor were also important for GRK-de

294 edema formation in sepsis by stimulation of beta2-adrenergic receptors, whereas the alpha1 adrenocep

295 l of ERK2 more efficiently than alpha 1b and beta2 adrenergic receptors, which form transient recepto

296 We observed that the content of beta2-adrenergic receptors, which are mainly expressed i

297 Activation of beta2 adrenergic receptors with salbutamol (40 microm) o

298 racellular and transmembrane portions of the beta2-adrenergic receptor with cytoplasmic domains of Rf

299 was inhibited by blockade of the beta1- and beta2-adrenergic receptors with propranolol, and by bloc

300 eviously to be required for recycling of the beta2 adrenergic receptor yet is functionally interchang